High production volumes, a reduction in the total cost of ownership, flexibility and a speedy delivery time are benefits claimed by Bosch for its new range of infeed systems launched this week at FachPack in Germany.
Sheffield Bio-Science takes on responsibility for global sales, distribution and development of Girus Life Sciences’ chemically defined Regocel supplements.
IDT Biologika unveils plans to expand viral vaccine contract manufacturing operations and says global capacity failing to keep pace with resurgence in drug industry demand.
Life Technologies has concluded license agreements, providing rights to its proprietary Chinese hamster ovary (CHO) cell lines for production of recombinant proteins used as therapeutic agents and vaccines.
Rexam and Med Time Technology, a US manufacturer of plastic prescription vials, have launched “Pill Timer,” a packaging solution designed to boost treatment compliance rates.
Pall has ended fiscal 2010 with strong set of sales after recovering pharmaceutical industry demand for bioproduction tech maintained its momentum in Q4
DSM Pharma Chemicals, a business unit of DSM Pharmaceutical Products, has announced the launch of InnoSyn route scouting services, meeting pharma needs to outsource process development R&D.
US formulation services provider Bend Research has received a new patent for the process of producing spray-dried solid amorphous dispersions of drugs using single-fluid pressure nozzles.
RecipharmCobra Biologics has received US and EU patent protection for an antibiotic resistance gene-free plasmid maintenance technology it claims can boost biomanufacturing yields.
NanGenex is introducing GMP bench-top and pilot plant reactors to scale-up its process for the continuous production of nanostructured active ingredients.
Tracking “non-content” metadata is an important part of any pharmaceutical submission, yet many drugmakers fail to take an integrated approach to the task according to regulatory expert Kate Wilber.
Cell culture, LAIV vaccines and recombinant DNA technology should be supported by the US government as part of a long-term overhaul of pandemic response capabilities, according to PCAST.
The US HHS is allocating $2bn (€1.6bn) to overhaul pandemic and bioterrorism capabilities through improvements to regulatory, developmental and manufacturing processes.
CardioGenics predicts yield boosting “biologics beads” will change the antibody extraction landscape after signing distribution deal with Merck Chimie.
Cel-Sci’s recently opened “Cold fill” facility has passed its first manufacturing test by completing filling of a batch of the candidate head and neck cancer drug Multikine for a late-stage trial.
Pfenex has won a US federal contract to use its expression technology for the rapid, cost-effective production of “unprecedented” amounts of anthrax vaccine.
In the first of a series of special in-pharmatechnologist podcasts Kate Wilber, Image Solutions’ (ISI) director of regulatory Services, Europe discusses the emerging trends in BPO and talks about how it can benefit drugmakers.
Cellexus has expanded its disposable bioreactor offering with a unit designed to give biomanufacturers greater flexibility in their choice of cell lines.
Emergent BioSolutions says additional biomanufacturing space at its Baltimore, Maryland plant could help reduce expenditure through use of new timesaving manufacturing tech.
Germany’s Merck KGaA has completed its $7bn (€b5.2n) acquisition of Millipore, unveiling plans to target “high-growth, high-margin” bio-research and bio-production markets.
A new study believes vaccine manufacturers from developing countries may be able to produce a HPV vaccine at a lower cost without infringing on the numerous patents drug makers have taken out on the vaccine technology.
Merck & Co is to close or sell eight manufacturing plants and a further eight R&D laboratories as part of efforts to cuts its workforce by 15 per cent.
Designed as a next generation cellulose-based virus removal filter, Planova™ S20N has demonstrated robust filtration performance for challenging molecules...
Bispecific antibodies (BisAbs), which can bind to two distinct antigens, are prone to high levels of aggregate (10-30%), challenging traditional platform...
Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...